申请人:SANOFI
公开号:US20200181223A1
公开(公告)日:2020-06-11
The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.
本发明涉及一种共轭物,其包括公式(I)的磺胺类化合物和活性药用成分,例如含有至少一处相对于母体胰岛素的突变的胰岛素类似物,其中该胰岛素类似物在B16位置发生突变,被疏水氨基酸取代和/或在B25位置发生突变,被疏水氨基酸取代。本发明还涉及公式(A)的磺胺类化合物。此外,本发明涉及一种相对于母体胰岛素至少发生一处突变的胰岛素类似物。